Actinium Pharmaceuticals

Actinium Pharmaceuticals

Actinium focuses on developing differentiated radiotherapies. Lead hematology programs Actimab-A, CD33 targeting AML therapeutic and Iomab-B, CD45 targeting BMT conditioning agent, are Phase 2/3 ready in alignment with FDA. Actimab-A is also being advanced under a CRADA with NCI to assess its mutation-agnostic and synergistic potential. Iomab-ACT (CD45) for cell and gene therapy conditioning is being studied in three Phase 1 trials . Actinium is seeking partners for its hematology programs.

Biotechnology, Bone Marrow Products, Clinical Research, Monoclonal Antibodies